Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug aims to revive failing cancer fighters in rare sarcomas

NCT ID NCT07261657

Recruiting now Disease control Sponsor: Seth Pollack Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests an immunotherapy drug called N-803 in up to 8 people with synovial sarcoma or myxoid/round cell liposarcoma whose cancer got worse after a prior cell therapy. N-803 is designed to boost the patient's own immune cells that survived the earlier treatment, helping them attack the cancer more effectively. The main goals are to see if the drug is safe and whether it can expand those rare immune cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYNOVIAL SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myxoid liposarcoma myxoid/round cell liposarcoma round cell liposarcoma synovial sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYXOID LIPOSARCOMA ROUND CELL LIPOSARCOMA SYNOVIAL SARCOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact